Aeglea BioTherapeutics Inc. priced an underwritten public offering of 3 million shares at $4.10 apiece to raise $12.3 million in gross proceeds.
The offering is expected to close June 9 with JonesTrading Institutional Services LLC acting as the sole book runner. The underwriter has an option to purchase up to an additional 450,000 of the shares offered.
Aeglea plans to use the net proceeds to fund its research and development product candidates and for other general corporate purposes.